Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 2, p. S78, 2018. DOI: 10.25251/skin.2.supp.78. Disponível em: https://skin.dermsquared.com/skin/article/view/474. Acesso em: 19 apr. 2025.